Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut

Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn’t dim Eli Lilly’s bright multiyear outlook, rendering the dip in the stock as a chance to buy.